Abstract:
Anxiety disorders represent one of the most prevalent mental health conditions worldwide, often leading to
significant impairment in social and occupational functioning. Modern management strategies focus not only
on symptom reduction but also on restoring functional capacity and improving quality of life. A synthesis of
recent clinical-scientific studies (2018–2024) was conducted, focusing on pharmacological interventions with
anxiolytic action and favorable tolerability profiles. Anxiety disorders exert a profound global burden, affecting
up to 20% of the population over a lifetime and ranking among the leading contributors to years lived with
disability. Beyond emotional suffering, chronic anxiety is associated with significant somatic symptoms,
cardiovascular disturbances, cognitive decline, and increased utilization of medical services. These factors
impair social functioning and diminish overall quality of life. Pharmacological management remains a
cornerstone of treatment, particularly in moderate to severe cases. Short- to medium-acting benzodiazepine
derivatives demonstrate rapid anxiolytic effects through potentiation of GABAergic neurotransmission,
leading to improved emotional regulation, normalization of sleep, and restoration of daily functioning.
Contemporary agents with reduced hepatic accumulation and lower dependence potential provide a safer
clinical profile, especially when administered for limited periods under strict medical supervision. Comparative
studies highlight that combining pharmacotherapy with cognitive-behavioral therapy results in greater
functional recovery and lower relapse rates than either modality administered alone. Furthermore, modern
clinical guidelines emphasize early intervention and an individualized approach to balance efficacy and safety.
The integrative approach that links neurochemical stabilization with psychotherapeutic adaptation promotes
durable recovery, enhances patient autonomy, and aligns with the modern paradigm of functionality-centered
psychiatric care.
